Indeed, EGFR amplification and mutation are invariably expressed in a heterogeneous manner, and the presence of EGFRvIII in a minor population of GBM cells has been shown to confer a more aggressive tumor phenotype through paracrine mechanisms [53]. The gene discussed is EGFR; the disease is glioblastoma.